The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix

Tsunehisa Kaku, Kenzo Sonoda, Toshiharu Kamura, Toshio Hirakawa, Kunihiro Sakai, Satoshi Amada, Shinji Ogawa, Hiroaki Kobayashi, Manabu Nakashima, Takeshi Watanabe, Hitoo Nakano

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4%, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.

Original languageEnglish
Pages (from-to)1449-1453
Number of pages5
JournalClinical Cancer Research
Volume5
Issue number6
Publication statusPublished - Jun 1 1999

Fingerprint

Neoplasm Antigens
Cervix Uteri
Adenocarcinoma
Survival
22-1-1 antigen
Lymph Nodes
Neoplasm Metastasis
Lymph
Uterus
Blood Vessels
Ovary
Neoplasms
Cytoplasm
Multivariate Analysis
Monoclonal Antibodies
Cell Membrane

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kaku, T., Sonoda, K., Kamura, T., Hirakawa, T., Sakai, K., Amada, S., ... Nakano, H. (1999). The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clinical Cancer Research, 5(6), 1449-1453.

The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. / Kaku, Tsunehisa; Sonoda, Kenzo; Kamura, Toshiharu; Hirakawa, Toshio; Sakai, Kunihiro; Amada, Satoshi; Ogawa, Shinji; Kobayashi, Hiroaki; Nakashima, Manabu; Watanabe, Takeshi; Nakano, Hitoo.

In: Clinical Cancer Research, Vol. 5, No. 6, 01.06.1999, p. 1449-1453.

Research output: Contribution to journalArticle

Kaku, T, Sonoda, K, Kamura, T, Hirakawa, T, Sakai, K, Amada, S, Ogawa, S, Kobayashi, H, Nakashima, M, Watanabe, T & Nakano, H 1999, 'The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix', Clinical Cancer Research, vol. 5, no. 6, pp. 1449-1453.
Kaku T, Sonoda K, Kamura T, Hirakawa T, Sakai K, Amada S et al. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clinical Cancer Research. 1999 Jun 1;5(6):1449-1453.
Kaku, Tsunehisa ; Sonoda, Kenzo ; Kamura, Toshiharu ; Hirakawa, Toshio ; Sakai, Kunihiro ; Amada, Satoshi ; Ogawa, Shinji ; Kobayashi, Hiroaki ; Nakashima, Manabu ; Watanabe, Takeshi ; Nakano, Hitoo. / The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 6. pp. 1449-1453.
@article{46e7f73e16d54477b30a84de7bdf35bf,
title = "The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix",
abstract = "We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4{\%}, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.",
author = "Tsunehisa Kaku and Kenzo Sonoda and Toshiharu Kamura and Toshio Hirakawa and Kunihiro Sakai and Satoshi Amada and Shinji Ogawa and Hiroaki Kobayashi and Manabu Nakashima and Takeshi Watanabe and Hitoo Nakano",
year = "1999",
month = "6",
day = "1",
language = "English",
volume = "5",
pages = "1449--1453",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix

AU - Kaku, Tsunehisa

AU - Sonoda, Kenzo

AU - Kamura, Toshiharu

AU - Hirakawa, Toshio

AU - Sakai, Kunihiro

AU - Amada, Satoshi

AU - Ogawa, Shinji

AU - Kobayashi, Hiroaki

AU - Nakashima, Manabu

AU - Watanabe, Takeshi

AU - Nakano, Hitoo

PY - 1999/6/1

Y1 - 1999/6/1

N2 - We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4%, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.

AB - We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4%, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.

UR - http://www.scopus.com/inward/record.url?scp=0032979473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032979473&partnerID=8YFLogxK

M3 - Article

C2 - 10389931

AN - SCOPUS:0032979473

VL - 5

SP - 1449

EP - 1453

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -